

Clinical Policy: Human Growth Hormone (Somapacitan, Somatrogen, Somatropin, Lonapegsomatropin-tcgd)

Reference Number: CP.CPA.353

Effective Date: 01.01.22

Last Review Date: 02.26

Line of Business: Commercial

[Coding Implications](#)
[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

The following human growth hormone (hGH) formulations require prior authorization:

- hGH analogs: somapacitan-beco (Sogroya[®]), somatrogen-ghla (Ngenla[™])
- Recombinant hGH (rhGH) formulations: somatropin (Genotropin[®], Humatrope[®], Norditropin[®], Nutropin AQ[®], NuSpin[®], Omnitrope[®], Saizen[®], Serostim[®], Zomacton[®], lonapegsomatropin-tcgd (Skytrofa[®])

Drugs	Children								Adults	
	GHD	PWS	TS	NS	SHOX	CKD	SGA	ISS	GHD	HIV
Sogroya	GF			GF			SS	SS	X	
Genotropin	GF	GF	GF				GF	GF	X	
Humatrope	GF		SS		SS/GF		SS	SS/GF	X	
Ngenla	GF									
Norditropin	GF	GF	SS	SS			SS	SS	X	
NutropinAQ	GF		GF			GF		GF	X	
Omnitrope	GF	GF	GF				GF	GF	X	
Saizen	GF								X	
Serostim										X
Skytrofa	GF								X	
Zomacton	GF		SS		SS		SS	SS	X	

Abbreviations: CKD: chronic kidney disease, GF: growth failure, GHD: growth hormone deficiency, HIV: human immunodeficiency virus, ISS: idiopathic short stature, NS: Noonan syndrome, PWS: Prader-Willi syndrome, SGA: small for gestational age, SHOX: short stature homeobox-containing gene, SS: short stature, TS: Turner syndrome

FDA Approved Indication(s)

hGH Analogs:

Sogroya is indicated for:

- Treatment of pediatric patients aged 2.5 years and older with: GF due to inadequate secretion of endogenous GH, SS born SGA and with no catch-up growth by 2 years of age, GF associated with NS, and ISS.
- Replacement of endogenous GH in adults with GHD.

Ngenla is indicated for:

- Treatment of pediatric patients aged 3 years and older who have GF due to inadequate secretion of endogenous GH.

rhGH Formulations:

Genotropin is indicated for treatment of:

- Children with GF due to GHD, PWS, SGA, TS, and ISS.
- Adults with either childhood-onset (CO) or adult-onset (AO) GHD.

Humatrope is indicated for treatment of:

- Pediatric patients: GF due to inadequate secretion of endogenous GH; SS associated with TS; ISS, high standard deviation score (SDS) <- 2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range; SS or GF in SHOX deficiency; SS born small for SGA with no catch-up growth by 2 years to 4 years of age.
- Replacement of endogenous GH in adults with GHD.

Norditropin FlexPro is indicated for the treatment of:

- Children with GF due to GHD, SS associated with NS, SS associated with TS, SS born SGA with no catch-up growth by age 2 to 4 years, ISS, and GF due to PWS.
- Replacement of endogenous GH in adults with GHD.

Nutropin AQ is indicated for the treatment of:

- Children with GF due to GHD, ISS, TS, and CKD up to the time of renal transplantation.
- Adults with either CO or AO GHD.

Omnitrope is indicated for the treatment of:

- Children with GF due to GHD, PWS, SGA, TS, and ISS.
- Adults with either CO or AO GHD.

Saizen is indicated for:

- Children with GF due to GHD.
- Adults with either CO or AO GHD.

Serostim is indicated for the treatment of:

- HIV patients with wasting or cachexia to increase lean body mass and body weight, and improve physical endurance.

Skytrofa is indicated for:

- Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have GF due to inadequate secretion of endogenous GH.
- Replacement of endogenous GH in adults with GHD.

Zomacton is indicated for:

- Treatment of pediatric patients who have GF due to inadequate secretion of endogenous GH, SS associated with TS, ISS, SS or GF in SHOX deficiency, and SS born SGA with no catch-up growth by 2 years to 4 years.
- Replacement of endogenous GH in adults with GHD.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Index

I. Initial Approval Criteria

- A. [Growth Hormone Deficiency with Neonatal Hypoglycemia \(off-label\)](#)
- B. [Growth Hormone Deficiency with Short Stature/Growth Failure - Children \(*open epiphyses*\)](#)
- C. [Genetic Disorders with Short Stature/Growth Failure - Children](#)
- D. [Chronic Kidney Disease with Growth Failure - Children](#)
- E. [Born Small for Gestational Age with Short Stature/Growth Failure - Children](#)
- F. [Idiopathic Short Stature - Children](#)
- G. [Growth Hormone Deficiency - Adults and Transition Patients \(*closed epiphyses*\)](#)
- H. [HIV-Associated Wasting/Cachexia - Adults](#)
- I. [Other diagnoses/indications](#)

II. Continuing Approval Criteria

- A. [All Pediatric Indications \(*open epiphyses*\)](#)
- B. [Growth Hormone Deficiency - Adults and Transition Patients \(*closed epiphyses*\)](#)
- C. [HIV-Associated Wasting/Cachexia - Adults](#)
- D. [Other diagnoses/indications](#)

III. Diagnoses/Indications for which coverage is NOT authorized:

IV. Appendices

V. Dosage and Administration

VI. Product Availability

VII. References

It is the policy of health plans affiliated with Centene Corporation[®] that Skytrofa, Sogroya, Ngenla, and somatropin are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

- A. **Growth Hormone Deficiency with Neonatal Hypoglycemia (off-label)** (must meet all):
 - 1. Diagnosis of neonatal hypoglycemia due to GHD;
 - 2. Request is for a somatropin formulation;
 - 3. Prescribed by or in consultation with a pediatric endocrinologist;
 - 4. Age \leq 1 month;
 - 5. Serum GH concentration \leq 5 μ g/L;
 - 6. Member meets one of the following (a or b):
 - a. Imaging shows hypothalamic-pituitary abnormality;
 - b. Deficiency of \geq 1 anterior pituitary hormone other than GH (e.g., ACTH, TSH, LH, FSH, prolactin);
 - 7. The requested product is not prescribed concurrently with Increlex[®] (mecasermin);
 - 8. If request is NOT for Norditropin or Humatrope, one of the following (a, b, or c):
 - a. Member must use Norditropin* and Humatrope*;
 - b. If both Norditropin and Humatrope are not available (e.g., due to drug shortages) member must use Omnitrope* vial, unless contraindicated or clinically significant adverse effects are experienced;
 - c. Norditropin, Humatrope, and Omnitrope are all contraindicated or clinically significant adverse effects are experienced;

**Prior authorization may be required for Norditropin, Humatrope, and Omnitrope*

9. Dose does not exceed 0.30 mg/kg per week.

Approval duration: 6 months or to member's renewal period whichever is longer

B. Growth Hormone Deficiency with Short Stature/Growth Failure - Children (*open epiphyses*) (must meet all):

1. Diagnosis of GHD;
2. Prescribed by or in consultation with a pediatric endocrinologist;
3. Age < 18 years;
4. If request is for Skytrofa, age \geq 1 years and weight \geq 11.5 kg;
5. If request is for Sogroya, age \geq 2.5 years;
6. If request is for Ngenla, age \geq 3 years;
7. If age > 10 years, open epiphysis on x-ray;
8. Member meets one of the following (a or b):
 - a. Low insulin-like growth factor (IGF)-I serum level;
 - b. Low insulin-like growth factor binding protein (IGFBP)-3 serum level;
9. Member meets one of the following (a, b, c, d, or e):
 - a. Two GH stimulation tests with peak serum levels \leq 10 μ g/mL (e.g., stimulants: arginine, clonidine, glucagon);
 - b. Deficiency of \geq 3 pituitary hormones (i.e., ACTH, TSH, LH, FSH, prolactin);
 - c. Prior surgery or radiotherapy to the hypothalamic-pituitary region;
 - d. Imaging shows hypothalamic-pituitary abnormality;
 - e. GHD-specific mutation (e.g., POU1F1, PROP1, LHX3, LHX4, HESX1, OTX2, TBX19, SOX2, SOX3, GLI2, GHRHR, GH1);
10. Member meets one of the following (a or b):
 - a. SS: height is > 2 SD below the mean for age and sex (SD, height, date, and age in months within the last 90 days are required);
 - b. GF: one of the following (i, ii, or iii):
 - i. Height deceleration across two growth chart percentiles representing > 1 SD below the mean for age and sex (SD and 2 heights, dates, and ages in months at least 6 months apart within the last year are required);
 - ii. Growth velocity > 2 SD below the mean for age and sex over 1 year (SD and 2 heights, dates, and ages in months at least 1 year apart within the last year are required);
 - iii. Growth velocity > 1.5 SD below the mean for age and sex sustained over 2 years (SD and 2 heights, dates, and ages in months at least 2 years apart within the last two years are required);
11. The requested product is not prescribed concurrently with Increlex (mecasermin);
12. If request is NOT for Norditropin or Humatrope, one of the following (a, b, or c):
 - a. Member must use Norditropin* and Humatrope*;
 - b. If both Norditropin and Humatrope are not available (e.g., due to drug shortages) member must use Omnitrope* vial, unless contraindicated or clinically significant adverse effects are experienced;
 - c. Norditropin, Humatrope, and Omnitrope are all contraindicated or clinically significant adverse effects are experienced;

**Prior authorization may be required for Norditropin, Humatrope, and Omnitrope*

13. Dose does not exceed one of the following (a, b, c, or d):
 - a. For Ngenla: 0.66 mg/kg once weekly;
 - b. For Skytrofa: 0.24 mg/kg once weekly;
 - c. For Sogroya: 0.16 mg/kg once weekly;
 - d. For somatropin agents: 0.30 mg/kg per week.

Approval duration: 6 months or to member's renewal period whichever is longer

C. Genetic Disorders with Short Stature/Growth Failure - Children (must meet all):

1. Diagnosis of PWS, TS, NS, or SHOX deficiency confirmed by a genetic test;
 2. Request is for one of the following (a or b):
 - a. Somatropin formulation;
 - b. Somapacitan formulation, and member has a diagnosis of NS;
 3. Prescribed by or in consultation with a pediatric endocrinologist;
 4. Age < 18 years;
 5. If age > 10 years, open epiphysis on x-ray;
 6. Member meets one of the following (a or b):
 - a. SS: height is > 2 SD below the mean for age and sex (> 1.5 SD if TS) (SD, height, date, and age in months within the last 90 days are required);
 - b. GF: one of the following (i, ii, or iii):
 - i. Height deceleration across two growth chart percentiles representing > 1 SD below the mean for age and sex (SD and 2 heights, dates, and ages in months at least 6 months apart within the last year are required);
 - ii. Growth velocity > 2 SD below the mean for age and sex over 1 year (SD and 2 heights, dates, and ages in months at least 1 year apart within the last year are required);
 - iii. Growth velocity > 1.5 SD below the mean for age and sex sustained over 2 years (SD and 2 heights, dates, and ages in months at least 2 years apart within the last two years are required);
 7. The requested product is not prescribed concurrently with Increlex (mecasermin);
 8. If request is NOT for Norditropin or Humatrope, one of the following (a, b, or c):
 - a. Member must use Norditropin* and Humatrope*;
 - b. If both Norditropin and Humatrope are not available (e.g., due to drug shortages) member must use Omnitrope* vial, unless contraindicated or clinically significant adverse effects are experienced;
 - c. Norditropin, Humatrope, and Omnitrope are all contraindicated or clinically significant adverse effects are experienced;
- *Prior authorization may be required for Norditropin, Humatrope, and Omnitrope*
9. Request meets one of the following (a or b):
 - a. For somatropin agents, one of the following (i, ii, or iii):
 - i. PWS: Dose does not exceed 0.24 mg/kg per week;
 - ii. TS, NS: Dose does not exceed 0.5 mg/kg per week;
 - iii. SHOX deficiency: Dose does not exceed 0.35 mg/kg per week;
 - b. Sogroya for NS: Dose does not exceed 0.24 mg/kg once weekly.

Approval duration: 6 months or to member's renewal period whichever is longer

D. Chronic Kidney Disease with Growth Failure – Children (must meet all):

1. Diagnosis of CKD;
 2. Request is for a somatotropin formulation;
 3. Prescribed by or in consultation with a pediatric endocrinologist or nephrologist;
 4. Age < 18 years;
 5. If age > 10 years, open epiphysis on x-ray;
 6. Member meets one of the following (a, b, c, or d):
 - a. GFR < 60 mL/min per 1.73 m² for ≥ 3 months;
 - b. Dialysis dependent;
 - c. Diagnosis of nephropathic cystinosis;
 - d. History of kidney transplant ≥ 1 year ago;
 7. Member meets one of the following (a or b):
 - a. SS: height is > 2 SD below the mean for age and sex (SD, height, date, and age in months within the last 90 days are required);
 - b. GF: one of the following (i, ii, or iii):
 - i. Height deceleration across two growth chart percentiles representing > 1 SD below the mean for age and sex (SD and 2 heights, dates, and ages in months at least 6 months apart within the last year are required);
 - ii. Growth velocity > 2 SD below the mean for age and sex over 1 year (SD and 2 heights, dates, and ages in months at least 1 year apart within the last year are required);
 - iii. Growth velocity > 1.5 SD below the mean for age and sex sustained over 2 years (SD and 2 heights, dates, and ages in months at least 2 years apart within the last two years are required);
 8. The requested product is not prescribed concurrently with Increlex (mecasermin);
 9. If request is NOT for Norditropin or Humatrope, one of the following (a, b, or c):
 - a. Member must use Norditropin* and Humatrope*;
 - b. If both Norditropin and Humatrope are not available (e.g., due to drug shortages) member must use Omnitrope* vial, unless contraindicated or clinically significant adverse effects are experienced;
 - c. Norditropin, Humatrope, and Omnitrope are all contraindicated or clinically significant adverse effects are experienced;
- *Prior authorization may be required for Norditropin, Humatrope, and Omnitrope*
10. Dose does not exceed 0.35 mg/kg per week.

Approval duration: 6 months or to member's renewal period whichever is longer

E. Born Small for Gestational Age with Short Stature/Growth Failure - Children (must meet all):

1. Diagnosis of SGA;
2. Request is for a somatotropin or somapacitan formulation;
3. Prescribed by or in consultation with a pediatric endocrinologist;
4. Age ≥ 2 years and < 18 years;
5. If age > 10 years, open epiphysis on x-ray;
6. Birth weight or length > 2 SD below the mean for gestational age (SD, birth weight or length, and gestational age are required);

7. Current height > 2 SD below the mean for age and sex measured within the last year at ≥ 2 years of age (SD, height, date, and age in months are required);
 8. The requested product is not prescribed concurrently with Increlex (mecasermin);
 9. If request is NOT for Norditropin or Humatrope, one of the following (a, b, or c):
 - a. Member must use Norditropin* and Humatrope*;
 - b. If both Norditropin and Humatrope are not available (e.g., due to drug shortages) member must use Omnitrope* vial, unless contraindicated or clinically significant adverse effects are experienced;
 - c. Norditropin, Humatrope, and Omnitrope are all contraindicated or clinically significant adverse effects are experienced;
- *Prior authorization may be required for Norditropin, Humatrope, and Omnitrope*
10. Request meets one of the following (a or b):
 - a. For somatropin agents: Dose does not exceed 0.48 mg/kg per week;
 - b. For Sogroya: Dose does not exceed 0.24 mg/kg once weekly.

Approval duration: 6 months or to member's renewal period whichever is longer

F. Idiopathic Short Stature - Children (must meet all):

1. Diagnosis of ISS;
 2. Request is for a somatropin or somapacitan formulation;
 3. Prescribed by or in consultation with a pediatric endocrinologist;
 4. Age < 18 years;
 5. If age > 10 years, confirmation of open epiphysis on x-ray;
 6. Member meets both of the following (a and b):
 - a. Height > 2.25 SD below the mean for age and sex (SD, height, date, and age in months within the last 90 days required);
 - b. Not likely to attain adult height in the normal range (predicted height is < 63 inches for males and < 59 inches for females);
 7. All the following conditions have been ruled out (a, b, and c):
 - a. Short stature related to GHD, genetic disease, CKD, SGA;
 - b. Familial (genetic) short stature (i.e., height velocity and bone age, as determined by x-ray, are within the normal range and one or both parents are short);
 - c. Constitutional delay of growth and puberty (i.e., the member's growth rate is delayed compared to chronological age but appropriate for bone age as determined by x-ray);
 8. The requested product is not prescribed concurrently with Increlex (mecasermin);
 9. If request is NOT for Norditropin or Humatrope, one of the following (a, b, or c):
 - a. Member must use Norditropin* and Humatrope*;
 - b. If both Norditropin and Humatrope are not available (e.g., due to drug shortages) member must use Omnitrope* vial, unless contraindicated or clinically significant adverse effects are experienced;
 - c. Norditropin, Humatrope, and Omnitrope are all contraindicated or clinically significant adverse effects are experienced;
- *Prior authorization may be required for Norditropin, Humatrope, and Omnitrope*
10. Request meets one of the following (a or b):
 - a. For somatropin agents: Dose does not exceed 0.5 mg/kg per week;
 - b. For Sogroya: Dose does not exceed 0.24 mg/kg once weekly.

Approval duration: 6 months or to member's renewal period whichever is longer

G. Growth Hormone Deficiency – Adults and Transition Patients (*closed epiphyses*)
(must meet all):

1. Diagnosis of GHD;
 2. Request is for a somatropin, somapacitan, or lonapegsomatropin formulation;
 3. Prescribed by or in consultation with an endocrinologist;
 4. Age \geq 18 years OR closed epiphysis on x-ray;
 5. Member has NOT received somatropin therapy for \geq 1 month prior to GH/IGF-I testing as outlined below;
 6. Member meets one of the following (a, b, or c):
 - a. Two fasting a.m. GH stimulation tests with peak serum levels \leq 5 μ g/mL (accepted stimulants: Macrilen[™] [macimorelin] or combination of 2 stimulants such as arginine + glucagon);
 - b. Both of the following (i and ii):
 - i. One fasting a.m. GH stimulation test with peak serum level \leq 5 μ g/ml (accepted stimulants: Macrilen [macimorelin] or combination of 2 stimulants such as arginine + glucagon);
 - ii. One low IGF-I serum level;
 - c. One low IGF-I serum level and (i, ii, or iii):
 - i. Imaging shows hypothalamic-pituitary abnormality;
 - ii. Deficiency of \geq 3 pituitary hormones (i.e., ACTH, TSH, LH, FSH, prolactin);
 - iii. GHD-specific mutation (e.g., POU1F1, PROP1, LHX3, LHX4, HESX1, OTX2, TBX19, SOX2, SOX3, GLI2, GHRHR, GH1);
 7. The requested product is not prescribed concurrently with Increlex (mecasermin);
 8. If request is NOT for Norditropin or Humatrope, one of the following (a, b, or c):
 - a. Member must use Norditropin* and Humatrope*;
 - b. If both Norditropin and Humatrope are not available (e.g., due to drug shortages) member must use Omnitrope* vial, unless contraindicated or clinically significant adverse effects are experienced;
 - c. Norditropin, Humatrope, and Omnitrope are all contraindicated or clinically significant adverse effects are experienced;
- *Prior authorization may be required for Norditropin, Humatrope, and Omnitrope*
9. Dose does not exceed one of the following (a, b, or c):
 - a. For Sogroya: 8 mg once weekly;
 - b. For somatropin agents: 0.4 mg/day (may adjust by up to 0.2 mg/day every 4 weeks to maintain normal IGF-1 serum levels; doses $>$ 1.6 mg/day would be uncommon);
 - c. For Skytrofa: 6.3 mg once weekly.

Approval duration: 6 months or to member's renewal period whichever is longer

H. HIV-Associated Wasting or Cachexia (must meet all):

1. Diagnosis of HIV;
2. Request is for a somatropin formulation;
3. Prescribed by or in consultation with a physician specializing in HIV management;
4. Age \geq 18 years;

5. Member meets one of the following (a, b, or c):
 - a. Unintentional weight loss of $\geq 10\%$ in the last 12 months occurring while on antiretroviral therapy;
 - b. Unintentional weight loss of $\geq 5\%$ in the last 6 months occurring while on antiretroviral therapy;
 - c. Body mass index (BMI) ≤ 20 kg/m²;
6. Failure of at least 2 pharmacologic therapies from two separate drug classes (*Appendix B*) unless contraindicated or clinically adverse effects are experienced;
7. Member is currently on antiretroviral therapy;
8. If request is NOT for Norditropin or Humatrope, one of the following (a, b, or c):
 - a. Member must use Norditropin* and Humatrope*;
 - b. If both Norditropin and Humatrope are not available (e.g., due to drug shortages) member must use Omnitrope* vial, unless contraindicated or clinically significant adverse effects are experienced;
 - c. Norditropin, Humatrope, and Omnitrope are all contraindicated or clinically significant adverse effects are experienced;
- *Prior authorization may be required for Norditropin, Humatrope, and Omnitrope*
9. Requested duration of therapy does not exceed 12 months;
10. Dose does not exceed 6 mg per day.

Approval duration: 6 months or to member's renewal period whichever is longer (up to 12 months total)

I. Other diagnoses/indications (must meet 1 and 2):

1. If request is NOT for Norditropin or Humatrope, one of the following (a, b, or c):
 - a. Member must use Norditropin* and Humatrope*;
 - b. If both Norditropin and Humatrope are not available (e.g., due to drug shortages) member must use Omnitrope* vial, unless contraindicated or clinically significant adverse effects are experienced;
 - c. Norditropin, Humatrope, and Omnitrope are all contraindicated or clinically significant adverse effects are experienced;
- *PA may be required for Norditropin, Humatrope, and Omnitrope*
2. Member meets one of the following (a or b):
 - a. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (i or ii):
 - i. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
 - ii. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
 - b. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 2a above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

II. Continued Therapy

A. All Pediatric Indications (*open epiphyses*) (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Age < 18 years OR open epiphysis on x-ray;
3. Member meets one of the following (a or b):
 - a. For diagnosis of neonatal hypoglycemia, when member has received somatropin therapy for ≥ 2 years, member's height has increased ≥ 2 cm in the last year as documented by 2 height measurements taken no more than 1 year apart (dates and height measurements required);
 - b. For all other pediatric diagnoses, member's height has increased ≥ 2 cm in the last year as documented by 2 height measurements taken no more than 1 year apart (dates and height measurements required);
4. If request is for a dose increase, request meets one of the following (a, b, c, or d):
 - a. For Ngenla for GHD (without neonatal hypoglycemia): New dose does not exceed 0.66 mg/kg once weekly;
 - b. For Skytrofa for GHD (without neonatal hypoglycemia): New dose does not exceed 0.24 mg/kg once weekly;
 - c. For Sogroya, one of the following (i or ii):
 - i. GHD (without neonatal hypoglycemia): New dose does not exceed 0.16 mg/kg once weekly;
 - ii. Born SGA, NS, ISS: New dose does not exceed 0.24 mg/kg once weekly;
 - d. For somatropin agents, one of the following (i, ii, iii, iv, or v):
 - i. GHD (with or without neonatal hypoglycemia): New dose does not exceed 0.30 mg/kg per week;
 - ii. PWS: New dose does not exceed 0.24 mg/kg per week;
 - iii. TS, NS, ISS: New dose does not exceed 0.5 mg/kg per week;
 - iv. SHOX deficiency, CKD: New dose does not exceed 0.35 mg/kg per week;
 - v. Born SGA: New dose does not exceed 0.48 mg/kg per week.

Approval duration: 6 months or to member's renewal period whichever is longer

B. Growth Hormone Deficiency - Adults and Transition Patients (*closed epiphyses*) (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;

3. For IGF-1 test results and dosing (test conducted within the last 90 days), one of the following (a, b, or c):
 - a. Low IGF-1 serum level: If request is for a dose increase, new dose does not exceed one of the following (i, ii, or iii):
 - i. For Sogroya: 8 mg once weekly;
 - ii. For somatropin formulations: Incremental increase of more than 0.2 mg/day and a total dose of 1.6 mg/day;
 - iii. For Skytrofa: 6.3 mg once weekly;
 - b. Normal IGF-1 serum level: Requested dose is for the same or lower dose;
 - c. Elevated IGF-1 serum level: Requested dose has been titrated downward.

Approval duration: 6 months or to member's renewal period whichever is longer

C. HIV-Associated Wasting/Cachexia - Adults (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. Member has not received \geq 12 months of therapy;
4. If request is for a dose increase, new dose does not exceed 6 mg per day.

Approval duration: 6 months or to member's renewal period whichever is longer (up to 12 months total)

D. Other diagnoses/indications (must meet 1 and 2):

1. If request is NOT for Norditropin or Humatrope, one of the following (a, b, or c):
 - a. Member must use Norditropin* and Humatrope*;
 - b. If both Norditropin and Humatrope are not available (e.g., due to drug shortages) member must use Omnitrope* vial, unless contraindicated or clinically significant adverse effects are experienced;
 - c. Norditropin, Humatrope, and Omnitrope are all contraindicated or clinically significant adverse effects are experienced;

**Prior authorization may be required for Norditropin, Humatrope, and Omnitrope*

2. Member meets one of the following (a or b):
 - a. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (I or ii):
 - i. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
 - ii. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
 - b. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT

authorized) AND criterion 2a above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.CPA.09 for commercial, or evidence of coverage documents;
- B. Constitutional delay of growth and puberty (i.e., constitutional growth delay; the member’s growth rate is delayed compared to chronological age but appropriate for bone age as determined by x-ray);
- C. Familial (genetic) short stature (i.e., height velocity and bone age, as determined by x-ray, are within the normal range and one or both parents are short);
- D. Adult short stature or altered body habitus associated with antiviral therapy (other than HIV-associated wasting or cachexia);
- E. Obesity treatment or enhancement of body mass/strength for non-medical reasons (e.g., athletic gains).

IV. Appendices/General Information

Appendix A: Abbreviation

AO: adult-onset	ISS: idiopathic short stature
CKD: chronic kidney disease	NS: Noonan syndrome
CO: childhood-onset	PWS: Prader-Willi syndrome
FDA: Food and Drug Administration	rhGH: recombinant human growth hormone
GF: growth failure	SD: standard deviation
GFR: glomerular filtration rate	SGA: small for gestational age
GH: growth hormone	SHOX: short stature homeobox-containing gene
GHD: growth hormone deficiency	SS: short stature
hGH: human growth hormone	TS: Turner syndrome
HIV: human immunodeficiency virus	
IGF-1: insulin-like growth factor-1	
IGFBP-3: insulin-like growth factor binding protein-3	

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug*	Dosing Regimen	Dose Limit/Maximum Dose
<i>Appetite Stimulants</i>		
megestrol (Megace [®] , Syndros [®])	400 – 800 mg PO daily (10 – 20 ml/day)	800 mg/day
dronabinol (Marinol [®])	2.5 mg PO BID	20 mg/day
<i>Testosterone Replacement Products</i>		
testosterone enanthate or cypionate (various brands)	50 – 400 mg IM Q2 – 4 wks	400 mg Q 2 wks

Drug*	Dosing Regimen	Dose Limit/Maximum Dose
Androderm [®] (testosterone transdermal patch)	2.5 – 7.5 mg patch applied topically QD	7.5 mg/day
testosterone transdermal gel (Androgel [®] , Testim [®])	5 – 10 gm gel (delivers 50 – 100 mg testosterone) applied topically QD	10 gm/day gel (100 mg/day testosterone)
Anabolic Steroids		
oxandrolone (Oxandrin [®])	2.5 – 20 mg PO /day	20 mg/day
Nausea/Vomiting Treatments		
chlorpormazine	10 to 25 mg PO q4 to 6 hours prn	2,000 mg/day
perphenazine	8 to 16 mg/day PO in divided doses	64 mg/day
prochlorperazine	5 to 10 mg PO TID or QID	40 mg/day
promethazine	12.5 to 25 mg PO q4 to 6 hours prn	50 mg/dose; 100 mg/day
trimethobenzamide	300 mg PO TID or QID prn	1,200 mg/day

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

*Preferred status may be formulary specific.

Appendix C: Contraindications/Boxed Warnings

- Contraindications:
 - Acute critical illness
 - Children with PWS who are severely obese, have history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to risk of sudden death
 - Active malignancy
 - Hypersensitivity to product or any of the excipients
 - Active proliferative or severe non-proliferative diabetic retinopathy
 - Children with closed epiphyses
- Boxed warning(s): none reported

Appendix D: Short Stature and Growth Failure

- For SS, the policy follows the World Health Organization (WHO) definition of > 2 SD below the mean for age and sex.¹
- For GF, the policy follows:
 - Haymond et al (2013) and Rogol et al (2014) for height deceleration across two major percentiles representing a change of > 1 SD corrected for age and sex^{2,3} and
 - the Growth Hormone Research Society (2000) for height velocity in the absence of SS that would prompt further investigation, namely, a height velocity > 2 SD below the mean over 1 year or > 1.5 SD below the mean sustained over 2 years for age and sex.⁴
- The Centers for Disease Control and Prevention (CDC) recommend WHO growth charts for infants and children age 0 to < 2 years and CDC growth charts for children age 2 years to < 20 years in the U.S.⁵

- Based on CDC recommended growth chart data, SD approximations of major height percentiles falling below the mean are listed below:
 - 2nd percentile: 2 SD below the mean
 - 5th percentile: 1.5 SD below the mean
 - 15th percentile: 1 SD below the mean
 - 30th percentile: 0.5 SD below the mean
 - 50th percentile: 0 SD mean
- CDC recommended growth charts, data tables, and related information that may be helpful in assessing length, height and growth are available at the following link: <https://www.cdc.gov/growthcharts/index.htm>.

1. WHO Child Growth Standards: Length/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height, and Body Mass Index-for-Age: Methods and Development. Geneva, Switzerland: World Health Organization; 2006. As cited in CDC. Division of Nutrition, Physical Activity, and Obesity. Growth Chart Training: Using the WHO Growth Charts. Page last reviewed January 13, 2022. Available at: <https://www.who.int/publications/i/item/924154693X>. Accessed December 3, 2024.
2. Haymond M, Kappelgaard AM, Czernichow P, et al. Early recognition of growth abnormalities permitting early intervention. *Acta Pædiatrica* ISSN 0803-5253. April 2013. DOI:10.1111/apa.12266.
3. Rogol AD, Hayden GF. Etiologies ad early diagnosis of short stature and growth failure in children and adolescents. *J Pediatr*. 2014 May;164(5 Suppl):S1-14.e6. doi: 10.1016/j.jpeds.2014.02.027.
4. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. *JCEM*. 2000; 85(11): 3990-3993.
5. Centers for Disease Control and Prevention, National Center for Health Statistics. CDC growth charts: United States. <http://www.cdc.gov/growthcharts/>. Accessed November 15, 2022.

V. Dosage and Administration

Drug Name	Indication	Dosing Regimen	Maximum Dose
<i>Pediatric Indications (Subcutaneous administration; weekly doses should be divided [except Skytrofa, Sogroya and Ngenla])</i>			
Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Zomacton	GHD	G, O: 0.16 to 0.24 mg/kg/week H, Z: 0.18 to 0.30 mg/kg/week N: 0.17 to 0.24 mg/kg/week Nu: to 0.30 mg/kg/week S: 0.18 mg/kg/week	See dosing regimens
Genotropin, Norditropin, Omnitrope	PWS	G, N, O: 0.24 mg/kg/week	0.24 mg/kg/week
Genotropin, Humatrope, Norditropin, Omnitrope, Zomacton	SGA	G, O: to 0.48 mg/kg/week H, N, Z: to 0.47 mg/kg/week	0.48 mg/kg/week
Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Zomacton	TS	G, O: 0.33 mg/kg/week H, Nu, Z: to 0.375 mg/kg/week N: to 0.47 mg/kg/week	See dosing regimens
Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Zomacton	ISS	G, O, No: to 0.47 mg/kg/week H, Z: to 0.37 mg/kg/week Nu: to 0.30 mg/kg/week	See dosing regimens
Humatrope, Zomacton	SHOX	H, Z: 0.35 mg/kg/week	0.35 mg/kg/week

Drug Name	Indication	Dosing Regimen	Maximum Dose
Norditropin	NS	0.46 mg/kg/week	0.46 mg/kg/week
Nutropin	CKD	0.35 mg/kg/week	0.35 mg/kg/week
Skytrofa	GHD	0.24 mg/kg once weekly	0.24 mg/kg/week
Sogroya	GHD	0.16 mg/kg once weekly	0.16 mg/kg/week
	SGA, NS, ISS	0.24 mg/kg once weekly	0.24 mg/kg/week
Ngenla	GHD	0.66 mg/kg once weekly	0.66 mg/kg/week
Adult Indications (Subcutaneous administration)			
Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Zomacton	GHD	0.4 mg/day – may adjust by increments up to 0.2 mg/day every 6 weeks to maintain normal IGF-1 serum levels.* <i>*Dosing regimen from Endocrine Society guidelines (Fleseriu, et al., 2016).</i> Adult GHD dosing should be substantially lower than that prescribed for children. Adult doses beyond 1.6 mg/day would be uncommon.	See dosing regimen
Serostim	HIV-associated wasting	0.1 mg/kg QOD or QD to 6 mg QD	6 mg/day up to 24 weeks
Skytrofa	GHD	<ul style="list-style-type: none"> 1.4 mg once weekly for adults 30 to 60 years old, with no oral estrogen intake 2.1 mg once weekly for adults < 30 years old, or adults of any age intaking oral estrogen 0.7 mg once weekly for adults > 60 years old, with no oral estrogen intake <p>Increase the dose monthly to a higher strength cartridge based on the clinical response and/or IGF-1 concentration</p>	6.3 mg/week
Sogroya	GHD	1.5 mg once weekly – increase by increments of 0.5-1.5 mg every 2-4 weeks based on	8 mg/week

Drug Name	Indication	Dosing Regimen	Maximum Dose
		clinical response and serum IGF-1 concentrations	

VI. Product Availability

Drug	Availability*
Genotropin lyophilized powder	MD dual-chamber syringes: 5 mg, 12 mg
Genotropin Miniquick	SD pen cartridges: 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1.0 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, and 2.0 mg
Humatrope	MD pen cartridges: 6 mg, 12 mg, 24 mg MD vial: 5mg
Ngenla	MD pens: 24 mg/1.2 mL, 60 mg/1.2 mL
Norditropin Flexpro	MD pens: 5 mg/1.5 mL, 10 mg/1.5 mL, 15 mg/1.5 mL, 30 mg/3 mL
Nutropin AQ	MD: NuSpin: 5 mg/2 mL, 10 mg/2 mL, 20 mg/2 mL MD pen cartridges: 10 mg/2 mL, 20 mg/2 mL
Omnitrope	MD pen cartridges: 5 mg/1.5 mL, 10 mg/1.5 mL MD vial: 5.8 mg
Saizen	MD pen cartridges: 8.8 mg MD vials: 5 mg, 8.8 mg
Serostim	MD vial: 4 mg SD vials: 5 mg, 6 mg
Skytrofa	SD prefilled cartridges: 0.7 mg, 1.4 mg, 1.8 mg, 2.1 mg, 2.5 mg, 3 mg, 3.6 mg, 4.3 mg, 5.2 mg, 6.3 mg, 7.6 mg, 9.1 mg, 11 mg, 13.3 mg
Sogroya	MD pens: 5 mg/1.5 mL, 10 mg/1.5 mL, 15 mg/1.5 mL
Zomacton	MD vials: 5 mg, 10 mg

SD: single-dose, MD: multidose

VII. References

FDA Labels

1. Genotropin Prescribing Information. NY, NY: Pfizer, Inc.; July 2025. Available at www.genotropin.com. Accessed November 6, 2025.
2. Humatrope Prescribing Information. Indianapolis, IN: Eli Lilly; July 2025. Available at: www.humatrope.com. Accessed November 6, 2025.
3. Ngenla Prescribing Information. New York, NY: Pfizer Labs; July 2025. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761184s006lbl.pdf. Accessed November 6, 2025.
4. Norditropin Prescribing Information. Plainsboro, NJ: Novo Nordisk; July 2025. Available at: www.norditropin.com. Accessed November 6, 2025.
5. Nutropin AQ. Prescribing Information. South San Francisco, CA: Genentech; July 2025. Available at: www.nutropin.com. Accessed November 6, 2025.
6. Omnitrope Prescribing Information. Princeton, NJ: Sandoz; July 2025. Available at: www.omnitrope.com. Accessed November 6, 2025.
7. Saizen Prescribing Information. Rockland, MA: Serono; February 2020. Available at: <https://www.emdserono.com/us-en/pi/saizen-ce-pi.pdf>. Accessed November 6, 2025.

8. Serostim Prescribing Information. Rockland, MA: EMD Serono Inc.; June 2019. Available at: <https://serostim.com/>. Accessed November 6, 2025.
9. Skytrofa Prescribing Information. Princeton, New Jersey: Ascendis Pharma Endocrinology Inc., July 2025. Available at: <https://skytrofa.com/>. Accessed November 6, 2025.
10. Sogroya Prescribing Information. Plainsboro, NJ: NovoNordisk Health Care AG; February 2026. Available at: <https://www.novo-pi.com/sogroya.pdf>. Accessed March 16, 2026.
11. Zomacton Prescribing information. Parsippany, NJ: Ferring Pharmaceuticals Inc., July 2025. Available at: www.zomacton.com. Accessed November 6, 2025.

Compendia

12. DRUGDEX[®] System [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically.
13. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2020. Available at <https://www.clinicalkey.com/pharmacology/>.

Somatropin Therapy – Children

14. Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. *Horm Res Paediatr* 2016; 86:361-397.
15. Rose SR, Cook DM, Fine MJ. Growth hormone therapy guidelines: Clinical and managed care perspectives. *Am J Pharm Benefits*. 2014;6(5):e134-e146.
16. Drube J, Wan M, Bonthuis M. Consensus statement: Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. *Nephrology*. September 2019; (15):S77-89.
17. National Kidney Foundation. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 Update. *Am J Kidney Dis* 53: S1-S124, 2009 (suppl 2).

GHD - Adults and Transition Patients

18. Yuen Keven CJ, Biller BMK, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology (AAACE) guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care: 2019 AAACE Growth Hormone Task Force. *Endocrine Practice*, November 2019; 25(11):1191-1232.
19. Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*, November 2016, 101(11):3888–3921 doi: 10.1210/jc.2016-2118.
20. Cook DM, Rose SR. A review of guidelines for use of growth hormone in pediatric and transition patients. *Pituitary*. September 2012, Volume 15, Issue 3, pp 301–310.
21. Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2011; 96: 1587-1609.

Short Bowel Syndrome

22. Pironi L, Arends J, Bozzetti F. ESPEN guidelines on chronic intestinal failure in adults. *Clinical Nutrition*. 2016; 35:247-307.
23. Iyer K, Dibaise JK, and Rubio-Tapia A. AGA clinical practice update on management of short bowel syndrome: expert review. *Clinical Gastroenterology and Hepatology* 2022;20:2184-2194.

HIV-Associated Wasting

24. Badowski ME, Perez SE. Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS. HIV AIDS (Auckl). 2016 Feb 10;8:37-45. doi: 10.2147/HIV.S81420. eCollection 2016.
25. Nemechek PM, Polsky B, Gottlieb M. Treatment guidelines for HIV-associated wasting. Subspecialty clinics: Infectious Diseases 2000;74(4):p386-394.
26. Wanke C, Kotler D, and the HIV Wasting Collaborative Consensus Committee. Collaborative recommendation: The approach to diagnosis and treatment of HIV wasting. Journal of Acquired Immune Deficiency Syndromes 2004;37;pS284-S288.
27. Bedimo R, Hardy D, Lee D, Palella F, and Wohl D. Expert consensus statement on an updated definition of unintended weight loss among persons with human immunodeficiency virus in the modern treatment era. CID 2024;79:S63-75.

Somatropin Product Comparative Data

28. Romer T, Zabransky M, Walczak M, Szalecki M, and Balser S. Effect of switching recombinant human growth hormone: comparative analysis of phase 3 clinical data. Biol Ther 2011; 1(2):005. DOI 10.1007/s13554-011-0004-8

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J2941	Injection, somatropin, 1 mg
C9399	Unclassified drugs or biologics
J3590	Unclassified biologics

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2022 annual review: no significant changes; modified Norditropin and Humatrope redirection to state member must use per template language; for adult GHD continuation of therapy added requirement that member is responding positively to therapy; for ISS clarified that both height criteria are required (SD and predicted height); RT4 Sogroya added new 5 mg/1.5 mL formulation; references reviewed and updated.	10.11.21	02.22
Template changes applied to other diagnoses/indications and continued therapy section.	09.29.22	
1Q 2023 annual review: FDA indication updated for Humatrope; for ISS, increased max dose to 0.5 mg/kg/week per PI; for HIV-associated wasting or cachexia added criteria member is currently on antiretroviral therapy; references reviewed and updated.	11.14.22	02.23

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Per February SDC and prior clinical guidance, added additional stepwise redirection to Omnitrope vial if Norditropin and Humatrope are not available (e.g., due to drug shortages).	02.21.23	05.23
RT4: per updated label for Sogroya – added pediatric extension for GF due to GHD and new 15 mg/1.5 mL strength, for pediatric GHD criteria set added Sogroya specific age limit and dosing, and updated Appendix C with Sogroya pediatric contraindications.	05.17.23	
RT4: added Ngenla to policy.	07.06.23	
1Q 2024 annual review: for HIV-associated wasting or cachexia, added options for member to meet criteria if weight < 90% of the lower limit of ideal body weight or BMI ≤ 20 kg/m ² ; added HCPCS/CPT code [C9399, J3590]; references reviewed and updated.	10.13.23	02.24
Added Skytrofa to policy.	05.31.24	08.24
1Q 2025 annual review: no significant changes; references reviewed and updated.	11.01.24	02.25
RT4: for Skytrofa, added new indication for replacement of endogenous GH in adults with GHD and added new cartridge strengths (0.7 mg, 1.4 mg, 1.8 mg, 2.1 mg, 2.5 mg).	09.17.25	
1Q 2026 annual review: removed Zorbtive from policy due to market discontinuation; removed criteria for short bowel syndrome due to lack of support by AGA; for HIV-associated wasting, added option for unintentional weight loss of ≥ 5% in the last 6 months while on antiretroviral and removed use of ideal body weight criteria per update 2024 consensus expert statement; references reviewed and updated.	11.06.25	02.26
RT4: per updated label for Sogroya, added new pediatric indications for SS born SGA, GF associated with NS, and ISS.	03.16.26	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does

not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2021 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.